Jazz to Present 21 Xywav Data Abstracts Including 11 Late-Breaking Studies
JAZZ•Jazz Pharmaceuticals will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026 in Baltimore from June 14-17, showcasing Xywav clinical and real-world data in narcolepsy and idiopathic hypersomnia. Key highlights include DUET post-hoc analyses on sleep inertia at dosages above baseline and LYRICAL longitudinal treatment patterns.
1. Conference Presentation Overview
Jazz Pharmaceuticals will unveil 21 abstracts, including 11 late-breaking studies, at SLEEP 2026 in Baltimore from June 14-17. Presentations cover Xywav oral solution data in narcolepsy and idiopathic hypersomnia, reflecting Jazz’s emphasis on both new clinical research and real-world evidence.
2. DUET Study Analyses
The DUET study post-hoc analyses include an oral presentation on objective and subjective sleep inertia in narcolepsy types 1 and 2, comparisons of hypersomnolence at dosages above 9 grams versus 9 grams per night, and stratified outcomes based on individual ideal sleep duration.
3. LYRICAL Real-World Evidence
Six poster presentations will report on the longitudinal, mixed-methods LYRICAL study examining U.S. adult dosing patterns, treatment experiences and quality-of-life associations in idiopathic hypersomnia and narcolepsy patients using Xywav, highlighting daytime and nighttime symptom improvements.
